trending Market Intelligence /marketintelligence/en/news-insights/trending/m_wdv78o5p1h7oyd6s0koa2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

OncoCyte to fund cancer test development through private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


OncoCyte to fund cancer test development through private placement

OncoCyte Corp. completed a private placement with two of its current investors for initial gross proceeds of $8 million.

One of the investors has committed to purchase an additional $2 million worth of shares prior to April 30.

All in all, the Alameda, Calif.-based biotechnology company will issue 7,936,508 common shares for $1.26 apiece.

Oncocyte intends to use the net proceeds to fund the development of its liquid biopsy diagnostic tests for the early detection of cancer, among other things.